Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Accumulated Expenses: 2015-2025

Historic Accumulated Expenses for Cartesian Therapeutics (RNAC) over the last 10 years, with Sep 2025 value amounting to $7.7 million.

  • Cartesian Therapeutics' Accumulated Expenses fell 18.51% to $7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.7 million, marking a year-over-year decrease of 18.51%. This contributed to the annual value of $12.1 million for FY2024, which is 22.45% down from last year.
  • Cartesian Therapeutics' Accumulated Expenses amounted to $7.7 million in Q3 2025, which was down 3.87% from $8.0 million recorded in Q2 2025.
  • Cartesian Therapeutics' Accumulated Expenses' 5-year high stood at $15.6 million during Q4 2023, with a 5-year trough of $6.8 million in Q1 2021.
  • For the 3-year period, Cartesian Therapeutics' Accumulated Expenses averaged around $10.8 million, with its median value being $9.5 million (2024).
  • As far as peak fluctuations go, Cartesian Therapeutics' Accumulated Expenses skyrocketed by 39.56% in 2022, and later tumbled by 30.69% in 2024.
  • Cartesian Therapeutics' Accumulated Expenses (Quarterly) stood at $10.5 million in 2021, then soared by 33.71% to $14.1 million in 2022, then rose by 10.57% to $15.6 million in 2023, then fell by 22.45% to $12.1 million in 2024, then dropped by 18.51% to $7.7 million in 2025.
  • Its Accumulated Expenses stands at $7.7 million for Q3 2025, versus $8.0 million for Q2 2025 and $9.2 million for Q1 2025.